Revenue and EPS growth trajectory
In its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018, a YoY rise of 6.3%. The company also reported adjusted EPS of $1.47 in fiscal 2018, a YoY rise of 16.67%.
Growth catalysts in fiscal 2019
According to the company’s fourth-quarter earnings conference call, Boston Scientific plans to launch four new endoscopy products in fiscal 2019. The company plans to reduce the probability of hospital-acquired infections through the launch of a single-use duodenoscope, Exalt D, in the fourth quarter of 2019. Additionally, the company aims to expand its offerings for pancreatic biliary procedures through the launch of the next-generation SpyGlass Visualization System, Orca pod valves, and Orisa gel, in fiscal 2019.
According to the company’s fourth-quarter earnings investor presentation, Boston Scientific plans to launch LithoVue Ureteroscope next generation and five new products for the kidney stone indication in fiscal 2019. The company also plans to launch SpaceOAR hydrogel, added to its portfolio through the acquisition of Augmenix and indicated for reducing side effects associated with radiation therapy for prostate cancer, in international markets in fiscal 2019.
In the neuromodulation segment, Boston Scientific plans to expand the number of approved indications for its deep brain stimulation platform in fiscal 2019. On January 24, 2019, the company issued a press release announcing the market launch of Vercise Primary Cell and Vercise Gevia DBS Systems.
According to the company’s fourth-quarter earnings conference call, Boston Scientific aims to launch innovative electrophysiology technologies such as the Apama RF (RadioFrequency) Balloon Catheter System and the Cryterion pulmonary vein isolation balloon in the atrial fibrillation indication in the EU market in fiscal 2019.
According to the company’s fourth-quarter earnings conference call, the launch of Eluvia in the US market has resulted in double-digit YoY revenue growth in the peripheral intervention segment revenues in the fourth quarter. The company expects to further report a rise in physician interest for its Eluvia system based on favorable results from the head-to-head Imperial trial. The company is also preparing to launch VICI Venous Stent in the US market in fiscal 2019.
Next, we’ll discuss recent and proposed product launches for Abbott Laboratories.